科藍軟件(300663.SZ):擬以1.07億元收購寧澤金融合計49%股權
格隆匯12月27日丨科藍軟件(300663.SZ)公佈,公司擬以現金人民幣1.0731億元收購張家界金澤企業管理合夥企業(有限合夥)、張家界銀澤企業管理合夥企業(有限合夥)、馬鞍山澤寶企業管理合夥企業(有限合夥)、貴州熙澤信息科技中心(有限合夥)、深圳君盛祥石股權投資基金合夥企業(有限合夥)、深圳君盛鼎石創業投資企業(有限合夥)分別持有的深圳寧澤科技有限公司(簡稱“標的公司”或“寧澤金融”)合計49.00%股權。此次收購完成後,公司將持有寧澤金融100%的股權,寧澤金融將成為公司的全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.